Depression and Anxiety Trial, Recruiting (NCT07422519)

Depression and Anxiety Trial, Recruiting NCT07422519 Sponsor: Hospital Universitari Vall d'Hebron Research Institute Condition: Depression and Anxiety

Printed from Voxsanity (voxsanity.com.au) — NCT07422519 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Depression And Anxiety

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are between 18 and 74 years old (inclusive)
You have been diagnosed with Major Depressive Disorder (MDD) — a serious form of depression — based on recognised medical guidelines (DSM-5)
Your current episode of depression has not improved enough after trying two or more antidepressant medications taken by mouth
Your current episode of depression has also not improved enough after trying at least one combination of medications or an add-on medication strategy
You are willing and able to sign a consent form agreeing to take part and to have your data collected

Who may not be able to join:

You have a medical reason why you cannot safely take esketamine (the study medication), based on its official prescribing guidelines
You are currently taking part in another clinical trial that involves antidepressant medication
You have a medical, mental health, or other condition that the trial doctor believes could put your safety or wellbeing at risk, or could affect the results of the study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 5 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +3493 274 6087

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07422519

Sponsor: Hospital Universitari Vall d'Hebron Research Institute

Phase: Not Applicable

Status: Recruiting

Condition: Depression and Anxiety

Trial contact: +3493 274 6087

More information: https://clinicaltrials.gov/study/NCT07422519

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are between 18 and 74 years old (inclusive)
You have been diagnosed with Major Depressive Disorder (MDD) — a serious form of depression — based on recognised medical guidelines (DSM-5)
Your current episode of depression has not improved enough after trying two or more antidepressant medications taken by mouth
Your current episode of depression has also not improved enough after trying at least one combination of medications or an add-on medication strategy
You are willing and able to sign a consent form agreeing to take part and to have your data collected

Who may not be able to join:

You have a medical reason why you cannot safely take esketamine (the study medication), based on its official prescribing guidelines
You are currently taking part in another clinical trial that involves antidepressant medication
You have a medical, mental health, or other condition that the trial doctor believes could put your safety or wellbeing at risk, or could affect the results of the study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 5 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Hospital Universitari Vall d'Hebron Research Institute

Registry

ClinicalTrials.gov

Start date

18 September 2025

Est. completion

15 December 2026

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Severity in depressive symptoms as assessed by Montgomery-Åsberg Depression Rating Scale (MADRS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov